Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mars, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
A randomized, double-masked and cross-over dietary intervention study to investigate the effects of diet supplementation with cocoa flavanols on arterial stiffness in healthy adult human subjects.
Cocoa flavanols (CF) are plant-derived compounds commonly present in the human diet. Examples of flavanol-containing foods and beverages are apples, chocolate, tea, wine, berries, pomegranate and nuts. Flavanols encompass a group of different compounds, and the final profile of flavanols in foods will depend on multiple factors including plant origin, time of harvesting, storage, food processing, and cooking techniques. The term "cocoa flavanols" (CF) as used here refers to the particular profile of flavanols and procyanidins naturally found in cocoa beans, and CF mainly consist of the monomeric flavanol (-)-epicatechin and its oligomeric derivatives (procyanidins) containing up to 10 monomer subunits.
Accumulating data resulting from dietary intervention studies suggest that the intake of diets rich in flavanols can exert a beneficial cardiovascular health effect in humans. However, most of these investigations have been conducted with patients with diverse health complications (e.g. hypertension, diabetes and coronary heart disease) rather than healthy subjects. Thus, the interpretation of these data in the context of nutrition, primary prevention, and dietary recommendations is limited. In the current study, the investigators propose to investigate the effects of cocoa flavanol intake on arterial stiffness in a healthy population of adults. The investigators submit that this investigation will provide novel insights into the potential health benefits of dietary flavanols and procyanidins in the context of cardiovascular health in humans. The data resulting from this study will be key to the design of larger scale studies in this context, which are needed to comprehensively study the role of dietary flavanols and procyanidins with regard to potential dietary recommendations and public health.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cocoa Flavanol intervention | Experimental | Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II. |
|
| Control intervention | Placebo Comparator | Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cocoa flavanols I | Other | Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Individual changes in systolic blood pressure (in office) | assessed as systolic blood pressure | Baseline and 2, 4, 6, 8 and 10 weeks following intervention |
| Individual changes in diastolic blood pressure (in office) | assessed as diastolic blood pressure | Baseline and 2, 4, 6, 8 and 10 weeks following intervention |
| Individual changes in augmentation index (in office) | assessed as augmentation index | Baseline and 2, 4, 6, 8 and 10 weeks following intervention |
| Individual changes in central blood pressure (in office) | assessed as central blood pressure | Baseline and 2, 4, 6, 8 and 10 weeks following intervention |
| Individual changes in blood pressure (at home) | self monitoring blood pressure | Daily for 2 weeks between 0, 2, 4, 6, 8 and 10 weeks of intervention |
| Individual changes in pulse wave velocity (in office) | assessed as pulse wave velocity | Baseline and 2, 4, 6, 8 and 10 weeks following intervention |
| Individual changes in lipid profile | Total cholesterol, LDL, HDL and Triglycerides | Baseline and 2, 4, 6, 8 and 10 weeks following intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Individual changes in flavanol metabolites in plasma and urine | flavanol/methylxanthine metabolites in plasma and urine | Baseline and 2, 4, 6, 8, 10 weeks following intervention |
| Individual changes in methylxanthine metabolites in plasma and urine |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carl L Keen, PhD | UC Davis | Principal Investigator |
| Javier I Ottaviani, PhD | Mars, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ragle Human Nutrition Research Center, Department of Nutrition at UC Davis | Davis | California | 95616 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20854838 | Background | Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH. Recommending flavanols and procyanidins for cardiovascular health: current knowledge and future needs. Mol Aspects Med. 2010 Dec;31(6):546-57. doi: 10.1016/j.mam.2010.09.008. Epub 2010 Sep 18. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Randomized, double-masked and cross-over dietary intervention study in healthy adults.
Not provided
Not provided
Not provided
| Control I | Other | Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks. |
|
| Cocoa flavanols II | Other | Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks. |
|
| Control II | Other | Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks. |
|
flavanol/methylxanthine metabolites in plasma and urine
| Baseline and 2, 4, 6, 8, 10 weeks following intervention |
| Individual changes in CMP | comprehensive metabolic panel | Baseline and 2, 4, 6, 8, 10 weeks following intervention |
| Individual changes in Step test performance | Volunteers will be asked to step up and down on a platform (7 inches high) at a rate of 23 steps per minute for no more than 3 minutes. Blood pressure will be measured before and after the step test. | Baseline and 2, 4, 6, 8, 10 weeks following intervention |